Suppr超能文献

131I甲状腺检查后的甲状腺癌风险:瑞典一项基于人群的队列研究

Thyroid cancer risk after thyroid examination with 131I: a population-based cohort study in Sweden.

作者信息

Dickman Paul W, Holm Lars-Erik, Lundell Göran, Boice John D, Hall Per

机构信息

Department of Medical Epidemiology, Karolinska Institutet, Stockholm, Sweden.

Swedish Radiation Protection Board, Stockholm, Sweden.

出版信息

Int J Cancer. 2003 Sep 10;106(4):580-587. doi: 10.1002/ijc.11258.

Abstract

Ionizing radiation is the only established cause of thyroid cancer, though the effect of diagnostic administration of (131)I on thyroid cancer risk appears minimal. The annual number of thyroid examinations using radioiodine is currently 5 per 1,000 individuals worldwide, so this issue is of public health importance. Our objective was to evaluate the excess risk of thyroid cancer following a range of known doses of (131)I administered for diagnostic purposes. We conducted a nationwide, population-based cohort study in Sweden including all 36,792 individuals who received (131)I for diagnostic purposes during 1952-1969 and were alive and free of thyroid cancer 2 years after exposure. Accrual of person-time at risk commenced 2 years after the first (131)I administration. Follow-up for cancer was to the end of 1998. Standardized incidence ratios (SIRs) were calculated as the ratio between the observed and expected numbers of thyroid cancers. Estimates were stratified by previous exposure to external radiation therapy to the neck, reason for thyroid examination, (131)I dose, sex, age at exposure and time since exposure. Thyroid cancers (n = 129) were diagnosed during 886,618 person-years at risk. Excess thyroid cancers were observed only among the 1,767 patients who reported previous external radiation therapy to the neck [SIR = 9.8, 95% confidence interval (CI) 6.3-14.6] and among those originally referred due to suspicion of a thyroid tumor (SIR = 3.5, 95% CI 2.7-4.4 for 11,015 patients without previous external radiation therapy). The 24,010 patients without previous exposure to external radiation therapy to the neck who were referred for a reason other than suspicion of a thyroid tumor received an estimated dose to the thyroid of 0.94 Gy. Among these patients, 36 thyroid cancers were observed compared to 39.5 expected (SIR = 0.91, 95% CI 0.64-1.26). We found no evidence that administration of (131)I for diagnostic purposes increases risk of thyroid cancer. However, our study included few patients under age 20, so the results apply primarily to exposure among adults. Our data suggest that protraction of dose may result in a lower risk than brief X-ray exposure of the same total dose.

摘要

电离辐射是甲状腺癌唯一已确定的病因,不过诊断性使用(131)I对甲状腺癌风险的影响似乎微乎其微。目前全球每1000人中每年进行放射性碘甲状腺检查的人数为5人,因此这个问题具有公共卫生重要性。我们的目的是评估一系列已知剂量用于诊断目的的(131)I给药后甲状腺癌的额外风险。我们在瑞典开展了一项全国性的基于人群的队列研究,纳入了1952年至1969年间所有因诊断目的接受(131)I治疗且在暴露后2年仍存活且无甲状腺癌的36792人。风险人时的累积从首次给予(131)I后2年开始。癌症随访至1998年底。标准化发病比(SIR)计算为观察到的甲状腺癌病例数与预期病例数之比。估计值按既往是否接受颈部外照射放疗、甲状腺检查原因、(131)I剂量、性别、暴露时年龄以及暴露后的时间进行分层。在886618人年的风险期内诊断出129例甲状腺癌。仅在报告既往有颈部外照射放疗的1767例患者中观察到额外的甲状腺癌病例[SIR = 9.8,95%置信区间(CI)6.3 - 14.6],以及在最初因怀疑甲状腺肿瘤而转诊的患者中观察到额外病例(对于11015例无既往颈部外照射放疗的患者,SIR = 3.5,95% CI 2.7 - 4.4)。24010例无既往颈部外照射放疗且因非怀疑甲状腺肿瘤原因转诊的患者,甲状腺估计接受剂量为0.94 Gy。在这些患者中,观察到36例甲状腺癌,预期为39.5例(SIR = 0.91,95% CI 0.64 - 1.26)。我们没有发现证据表明诊断性使用(131)I会增加甲状腺癌风险。然而,我们的研究纳入的20岁以下患者很少,所以结果主要适用于成人暴露情况。我们的数据表明,剂量延长可能比相同总剂量的短时间X线照射导致的风险更低。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验